We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosures
- Chronic migraine
- Chronic Daily Headache and Evolution of the term Chronic Migraine
- Chronic daily headache (CDH) (1)
- Chronic daily headache (CDH) (2)
- Chronic daily headache (CDH) (3)
- Evolution of diagnostic terms
- The 4 types of CDH
- Transformed migraine (TM)
- Silberstein-Lipton approach
- ICHD-1 to ICHD-2
- ICHD-2 (2004)
- Problems with ICHD-2 CM
- MOH and IHCD-2 (2004)
- The Heisenberg Uncertainty Principle of MOH in ICHD-2
- ICHD-2 revised CM: A1.5.1 (2006)
- MOH, revised, ICHD-2 (2005)
- Revised MOH A8.2 (2006)
- ICHD-3 definition of CM
- ICHD-3 criteria for MOH
- The US FDA cuts the Gordian Knot
- Other CDH types: CTTH
- Chronic tension-type headache (CTTH)
- CM: clinical picture
- What does CM look like clinically?
- CM is mostly migraine days
- Progression to MOH/CM
- The boundary between EM and CM
- Are the current definitions of HFEM and CM correct?
- PRO measurement analysis
- Imaging does differentiate EM from CM with ICHD3 criteria
- Extensive imaging studies
- New proposed CM criteria
- CM and acute MO
- Is CM with acute medication overuse secondary or one disorder?
- Is CM with acute medication overuse different than MOH?
- Onabot responders
- Anti-CGRP therapy
- Eptinezumab conversion from CM with MOH to EM in 3 months
- Galcanezumab worked equally well in EM and CM with MO
- Atogepant reduced MMDs WWO MO
- Changes in EM/CM/MOH diagnoses and treatment paradigm
- Changes: diagnoses & treatment paradigm
- One way to put this together
- Oxygen:fire as CGRP:migraine
- Conclusions
- Acknowledgements
Topics Covered
- Chronic migraine
- Chronic Daily Headache (CDH)
- Transformed Migraine (TM)
- Silberstein-Lipton approach
- ICHD-3 Criteria for MOH
- Chronic Tension-Type Headache (CTTH)
- Boundary between CM and EM
- New proposed CM criteria
- Onabot responders
- Anti-CGRP therapy
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Tepper, S.J. (2024, January 31). Chronic migraine: history, imaging and patient characteristics, and controversies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/QPZF5089.Export Citation (RIS)
Publication History
Financial Disclosures
- Research funding: Abbvie, Aeon, Amgen, Annovis, Axsome, Cassava, Cognition, Eli Lilly, Inhibikase, Ipsen, Lundbeck, Merz, Neurolief, Pfizer, PrecisionMed, Revance, Scilex, Suven, UCB. Consultant and/or Advisory Boards (honoraria): Abbvie, Aeon, Alphasights, Amgen, Aruene/eNeura, Atheneum, Axsome Therapeutics, Becker Pharmaceutical Consulting, ClearView Healthcare Partners, ClickTherapeutics, CoolTech, CRG, Decision Resources, Defined Health, DRG, Eli Lilly, ExpertConnect, FCB Health, Fenix, GLG, Guidepoint Global, Health Advances, Health Science Communications, HMP Communications, Impel, Initiator Pharma, InteractiveForums, Keyquest, Ki Health Partners, Krog and Partners, Lundbeck, M3 Global Research, Magellan Health, Magnolia Innovation, Miravo Healthcare, MJH Holdings, Neurofront Therapeutics, Neurolief, Nocira, Novartis, P Value Communications, Pain Insights, Inc, Palion Medical, Perfood, Pfizer, Pulmatrix, Putnam Associates, Rehaler, SAI MedPartners, Satsuma, Scilex, Slingshot Insights, Spherix Global Insights, Strategy Inc, Synapse Medical Communication, System Analytic, Taylor and Francis, Tegus, Teva, Theranica, Tonix, Trinity Partners, Unity HA, Vial, XOC. Salary: Dartmouth-Hitchcock Medical Center, Thomas Jefferson University, Ki Health Partners. Speakers Bureau: AbbVie, Eli Lilly, Pfizer, Scilex, Teva. CME honoraria: American Academy of Neurology, American Headache Society, Annenberg Center for Health Sciences, Catamount Medical Education, Diamond Headache Clinic, Forefront Collaborative, Haymarket Medical Education, HMP Global, Medical Education Speakers Network, Medical Learning Institute Peerview, Migraine Association of Ireland, Miller Medical Education, National Association for Continuing Education, North American Center for CME, The Ohio State University, Physicians’ Education Resource, PlatformQ Education, Primed, Vindico Medical Education, WebMD/Medscape.
Chronic migraine: history, imaging and patient characteristics, and controversies
Published on January 31, 2024
48 min
Other Talks in the Series: Toward a Deeper Understanding of Headache and Migraine
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Stewart Tepper,
Vice President of The New
England Institute for
Neurology and Headache
in Stamford, Connecticut.
I'm going to talk about
chronic migraine; history,
imaging, patient characteristics,
and controversies.
0:20
These are my disclosures.
I work extensively with the
industry to try to bring
new therapies for patients,
so please bear that in mind.
0:31
What I'd like to
talk about today
is the entire arc of how we
got to where we are
with respect to
chronic migraine in terms
of both diagnosis and treatment.
In so doing, I'm going to
discuss chronic daily headache,
chronic migraine, transformed
migraine, medication
overuse headache,
and chronic
tension-type headache.
Because there is a history of
confused taxonomy and problems
with the diagnosis of
these various forms.
So, I would like to go into
the clinical issues of
phenotype diagnosis
and treatment
versus primary and
secondary divisions
with insights into
chronic migraine by
patient reported outcomes,
imaging, and studies.
I would like to end up on
the relationship between
diagnosis and acute
medication overuse and
an approach in terms of
clinical treatment
in the 21st century.
1:34
We'll start with diagnosis.
The evolution of the
term chronic migraine
from chronic daily headache.
Hide